<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03964727</url>
  </required_header>
  <id_info>
    <org_study_id>IMMU-132-11</org_study_id>
    <nct_id>NCT03964727</nct_id>
  </id_info>
  <brief_title>Study of Sacituzumab Govitecan-hziy in Metastatic Solid Tumors</brief_title>
  <acronym>TROPiCS-03</acronym>
  <official_title>A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to to assess the objective response rate (ORR) of&#xD;
      sacituzumab govitecan-hziy in adult participants with metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessment</measure>
    <time_frame>Up to end of treatment (average 3 years)</time_frame>
    <description>ORR, is defined as the rate of the overall best response, complete response (CR) or partial response (PR), based on the investigator-assessed tumor response using RECIST 1.1 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) According to RECIST 1.1 by Blinded Independent Central Review (BICR) Assessment</measure>
    <time_frame>Up to end of treatment (average 3 years)</time_frame>
    <description>ORR, is defined as the rate of the overall best response, CR or PR, by BICR using RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) According to RECIST 1.1 by BICR</measure>
    <time_frame>Up to end of treatment (average 3 years)</time_frame>
    <description>DOR, is calculated as the date of the first evaluation showing documented response, either PR or CR, to the date of the first progression of disease (PD) or death according to RECIST 1.1 by BICR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR) According to RECIST 1.1 by BICR</measure>
    <time_frame>Up to end of treatment (average 3 years)</time_frame>
    <description>CBR is defined as CR + PR + stable disease (SD) according to RECIST 1.1 by BICR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) According to RECIST 1.1 by BICR</measure>
    <time_frame>Up to end of treatment (average 3 years)</time_frame>
    <description>PFS, is defined as the time from first dose until objective tumor progression or death, whichever comes first according to RECIST 1.1 by BICR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR According to RECIST 1.1 by Investigator's Assessment</measure>
    <time_frame>Up to end of treatment (average 3 years)</time_frame>
    <description>DOR, is calculated as the date of the first evaluation showing documented response, either PR or CR, to the date of the first PD or death based on the investigator-assessed tumor response using RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR) According to RECIST 1.1 by Investigator's Assessment</measure>
    <time_frame>Up to end of treatment (average 3 years)</time_frame>
    <description>CBR, is defined as CR + PR + SD based on the investigator-assessed tumor response using RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) According to RECIST 1.1 by Investigator's Assessment</measure>
    <time_frame>Up to end of treatment (average 3 years)</time_frame>
    <description>PFS, is defined as the time from first dose until objective tumor progression or death, whichever comes first according to RECIST 1.1 based on the investigator-assessed tumor response using RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast Cell-surface Antigen-2 (TROP-2) Expression Level</measure>
    <time_frame>Up to end of treatment (average 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs)</measure>
    <time_frame>First dose date up to last dose date plus 30 days (average 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs)</measure>
    <time_frame>First dose date up to last dose date plus 30 days (average 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing any Clinically Significant Laboratory Abnormalities</measure>
    <time_frame>First dose date up to last dose date plus 30 days (average 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Cmax of Sacituzumab Govitecan-hziy</measure>
    <time_frame>First dose date up to last dose date plus 30 days (average 3 years)</time_frame>
    <description>Cmax is defined as the maximum observed concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: AUC0-168h of Sacituzumab Govitecan-hziy</measure>
    <time_frame>First dose date up to last dose date plus 30 days (average 3 years)</time_frame>
    <description>AUC0-168h is defined as the concentration of drug over time between time 0 and time 168 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Tmax of Sacituzumab Govitecan-hziy</measure>
    <time_frame>First dose date up to last dose date plus 30 days (average 3 years)</time_frame>
    <description>Tmax is defined as time to maximum observed concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Assessment</measure>
    <time_frame>First dose date up to last dose date plus 30 days (average 3 years)</time_frame>
    <description>Number of participants who test positive for anti-drug antibodies to sacituzumab govitecan-hziy will be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Metastatic Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Sacituzumab Govitecan-hziy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with non-small cell lung cancer (NSCLC), head and neck squameous cell carcinoma (HNSCC), or endometrial cancer will receive sacituzumab govitecan-hziy 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle until disease progression (PD), toxicity or withdrawal of consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacituzumab Govitecan-hziy</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>Sacituzumab Govitecan-hziy</arm_group_label>
    <other_name>IMMU-132</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Able to understand and give written informed consent.&#xD;
&#xD;
          -  Individuals with the following histologically documented metastatic (M1, Stage IV) or&#xD;
             locally advanced solid tumors. Tumor blocks (preferably, obtained within 12 months of&#xD;
             study entry if clinically feasible) or 20 newly sectioned slides (6 minimum) of&#xD;
             archived biopsy/surgical specimens are requested. these specimens should be submitted&#xD;
             within 28 days before initiating Screening, after the individual provides written&#xD;
             informed consent. A baseline biopsy is required if archival tissue is not available.&#xD;
             Fine needle aspirations and bone biopsies are not suitable samples.&#xD;
&#xD;
               -  Non-small cell lung cancer (NSCLC) (adenocarcinoma or squamous cell carcinoma&#xD;
                  (SCC)), that has progressed after prior platinum-based chemotherapy and&#xD;
                  Programmed death-ligand 1 (PD-L1) or Programmed cell death protein 1 (PD-1)&#xD;
                  directed therapy; recurrence/ relapse or lack of response within 6 months of&#xD;
                  completion of chemotherapy for locally advanced disease, that line of therapy may&#xD;
                  be counted for eligibility.&#xD;
&#xD;
               -  Incurable, recurrent, or metastatic HNSCC that has progressed after prior&#xD;
                  platinum based chemotherapy and PD-LI or PD-1 directed therapy&#xD;
&#xD;
               -  Relapsed unresectable endometrial cancer that has progressed after prior platinum&#xD;
                  based chemotherapy or is refractory to platinum based chemotherapy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance status score of 0 or 1&#xD;
&#xD;
          -  Adequate hematologic counts without transfusional or growth factor support within 2&#xD;
             weeks of study drug initiation&#xD;
&#xD;
          -  Adequate hepatic function&#xD;
&#xD;
          -  Individual must have at least a 3-month life expectancy&#xD;
&#xD;
          -  Have measurable disease by Computed Tomography (CT) or Magnetic Resonance Imaging&#xD;
             (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Tumor&#xD;
             lesions situated in a previously irradiated area may be utilized if they are&#xD;
             considered measurable and progression has been demonstrated in such lesions.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Have had a prior anti-cancer biologic agent within 4 weeks prior to study Day 1 or&#xD;
             have had prior chemotherapy, targeted small molecule therapy, radiation therapy within&#xD;
             2 weeks prior to Study Day 1&#xD;
&#xD;
          -  Have not recovered (i.e., ≤ Grade 1) from adverse events due to a previously&#xD;
             administered agent&#xD;
&#xD;
          -  Have previously received topoisomerase I inhibitors&#xD;
&#xD;
          -  Have an active second malignancy&#xD;
&#xD;
          -  Have known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis. Individuals with previously treated brain metastases may participate&#xD;
             provided they have stable CNS disease for at least 4 weeks prior to the first dose of&#xD;
             study drug and all neurologic symptoms have returned to baseline, have no evidence of&#xD;
             new or enlarging brain metastases and are taking ≤20 mg/day of prednisone or its&#xD;
             equivalent. All individuals with carcinomatous meningitis are excluded regardless of&#xD;
             clinical stability&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>USOR - Arizona Oncology - Glendale - Saguaro Cancer Center</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Los Angeles Hematology Oncology Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute at Baptist Health, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Rogel Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center - Hematology and Oncology - Tupelo</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine - Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology - Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine - Upper East Side</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute and Research Center - Eugene</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Blue Ridge Cancer Care - Wytheville</name>
      <address>
        <city>Blacksburg</city>
        <state>Virginia</state>
        <zip>24060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018 Jun 22;9(48):28989-29006. doi: 10.18632/oncotarget.25615. eCollection 2018 Jun 22. Review.</citation>
    <PMID>29989029</PMID>
  </reference>
  <reference>
    <citation>Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, Schneider BJ, Ocean A, Johnson T, Gandhi L, Kalinsky K, Scheff R, Messersmith WA, Govindan SV, Maliakal PP, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM. Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. Clin Cancer Res. 2017 Oct 1;23(19):5711-5719. doi: 10.1158/1078-0432.CCR-17-0933. Epub 2017 Jul 5.</citation>
    <PMID>28679770</PMID>
  </reference>
  <reference>
    <citation>Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer. 2017 Oct 1;123(19):3843-3854. doi: 10.1002/cncr.30789. Epub 2017 May 30.</citation>
    <PMID>28558150</PMID>
  </reference>
  <reference>
    <citation>Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. J Clin Oncol. 2017 Aug 20;35(24):2790-2797. doi: 10.1200/JCO.2016.72.1894. Epub 2017 May 26.</citation>
    <PMID>28548889</PMID>
  </reference>
  <reference>
    <citation>Bourauel C, Drescher D, Nolte LP. [The computer-aided development of orthodontic treatment elements made from NiTi memory alloys exemplified by a pseudoelastic retraction spring]. Fortschr Kieferorthop. 1993 Feb;54(1):45-56. German. Erratum in: Fortschr Kieferorthop 1993 Apr;54(2):9.</citation>
    <PMID>8503956</PMID>
  </reference>
  <reference>
    <citation>Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14.</citation>
    <PMID>28291390</PMID>
  </reference>
  <reference>
    <citation>Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa AA, Goldenberg DM. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer. Clin Cancer Res. 2017 Jul 1;23(13):3405-3415. doi: 10.1158/1078-0432.CCR-16-2401. Epub 2017 Jan 9.</citation>
    <PMID>28069724</PMID>
  </reference>
  <reference>
    <citation>Faltas B, Goldenberg DM, Ocean AJ, Govindan SV, Wilhelm F, Sharkey RM, Hajdenberg J, Hodes G, Nanus DM, Tagawa ST. Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. Clin Genitourin Cancer. 2016 Feb;14(1):e75-9. doi: 10.1016/j.clgc.2015.10.002. Epub 2015 Oct 19.</citation>
    <PMID>26541586</PMID>
  </reference>
  <reference>
    <citation>Sharkey RM, McBride WJ, Cardillo TM, Govindan SV, Wang Y, Rossi EA, Chang CH, Goldenberg DM. Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan). Clin Cancer Res. 2015 Nov 15;21(22):5131-8. doi: 10.1158/1078-0432.CCR-15-0670. Epub 2015 Jun 23.</citation>
    <PMID>26106073</PMID>
  </reference>
  <reference>
    <citation>Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015 Sep 8;6(26):22496-512. Erratum in: Oncotarget. 2020 Mar 10;11(10):942.</citation>
    <PMID>26101915</PMID>
  </reference>
  <reference>
    <citation>Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJ Jr, Vahdat LT, Thomas SS, Govindan SV, Maliakal PP, Wegener WA, Hamburger SA, Sharkey RM, Goldenberg DM. First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. Clin Cancer Res. 2015 Sep 1;21(17):3870-8. doi: 10.1158/1078-0432.CCR-14-3321. Epub 2015 May 5.</citation>
    <PMID>25944802</PMID>
  </reference>
  <reference>
    <citation>Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, Rossi EA, Chang CH, Goldenberg DM. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31. doi: 10.1021/acs.bioconjchem.5b00223. Epub 2015 May 8.</citation>
    <PMID>25915780</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

